Comparative genomic hybridization (CGH) and conventional cytogenetic karyotyping were used to screen for losses and gains of DNA sequences along chromosomes in ten renal tumors (RCC) of different histologic types (clear-cell RCC, papillary RCC, and one oncocytoma). Loss of 3p was the most common change in clear-cell RCC. All papillary tumors, either adenomas or carcinomas revealed gains of chromosomes 7 and 17q without limitation to size and grade. Homozygotic loss of the pseudoautosomal Xp or Yp region was detected in three RCC tumors. A dicentric (Y;14) was present as the sole chromosome abnormality in the oncocytoma. Both techniques showed concordant results in tumors with homogeneous karyotype. However, in tumors with several composite clones some discrepancies were observed, especially in cases of clear-cell RCC where chromosomal abnormalities present in a low number of metaphases could not be detected by CGH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0165-4608(02)00544-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TDERS, an exosome RNA-derived signature predicts prognosis and immunotherapeutic response in clear cell renal cell cancer: a multicohort study.
J Natl Cancer Cent
December 2024
Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
Background: Tumor-derived exosomes are involved in tumor progression and immune invasion and might function as promising noninvasive approaches for clinical management. However, there are few reports on exosom-based markers for predicting the progression and adjuvant therapy response rate among patients with clear cell renal cell carcinoma (ccRCC).
Methods: The signatures differentially expressed in exosomes from tumor and normal tissues from ccRCC patients were correspondingly deregulated in ccRCC tissues.
Immunohistochemical Analysis of a1-Acid Glycoprotein and Tumor Associated Macrophages in Clear Cell Renal Cell Carcinoma.
Cancer Genomics Proteomics
December 2024
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan;
Background/aim: α1-Acid glycoprotein (AGP), also known as orosomucoid, is an acute-phase protein that has been found increased in plasma of cancer patients. This study investigates the role of AGP expression in clear cell renal cell carcinoma (ccRCC) and its association with clinical outcomes.
Materials And Methods: We investigated the correlation between AGP levels and the prognosis of ccRCC through an analysis of The Cancer Genome Atlas (TCGA) database.
Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma.
Neoplasia
December 2024
Radboud University Medical Center, 6525 GA, Nijmegen, the Netherlands.
Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). With modest OS improvement and variable response and toxicity predictive and/or prognostic biomarkers are needed to personalize patient management: Prediction of individual TKI therapy response and resistance will increase successful treatment outcome while reducing unnecessary drug use and expense. The aim of this study was to investigate whether kinase activity analysis can predict sunitinib response and/or toxicity using tissue samples obtained from primary clear cell RCC (ccRCC) from a cohort of clinically annotated patients with mRCC receiving sunitinib as first-line treatment.
View Article and Find Full Text PDFMetastasis of clear cell renal cell carcinoma to hyalinizing trabecular tumor of the thyroid: A case report.
Oncol Lett
March 2025
Department of Pathology, Beilun District People's Hospital of Ningbo City, Ningbo, Zhejiang 315000, P.R. China.
Renal cell carcinoma (RCC) is the most common malignancy that metastasizes to the thyroid; however, metastasis of RCC to a primary tumor of the thyroid is rare. The present study reports the case of RCC that had metastasized to the primary thyroid tumor; namely, a hyalinizing trabecular tumor (HTT). Notably, the RCC was resected 2 years prior.
View Article and Find Full Text PDFApplication of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor.
Int Urol Nephrol
December 2024
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, 610041, Sichuan, People's Republic of China.
Purpose: To evaluate the efficacy and safety of extended immunotherapy in first-line immune checkpoint inhibitors (ICIs)-tyrosine kinase inhibitors (TKIs) combination treatment for advanced renal cell carcinoma (RCC).
Patients And Methods: We retrospectively analyzed data from patients with advanced RCC who received first-line ICIs-TKIs combination treatment at West China Hospital of Sichuan University between October 2018 and July 2024. Patients who are assessed as having a disease control status after 2 years of continuous treatment will continue to receive immune checkpoint inhibitors until the inhibitors are discontinued due to disease progression or death.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!